Current and future use of dipyridamole in patients with COVID-19
Current use of dipyridamole in COVID-19 is mainly based on its antithrombotic activity, since there is no robust clinical effectiveness data. The decision to use dipyridamole in COVID-19 should be individualized, considering the experimental nature of this treatment.
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Russo |
| Argitaratua: |
Izdatelstvo OKI
2020-10-01
|
| Saila: | Качественная клиническая практика |
| Gaiak: | |
| Sarrera elektronikoa: | https://www.clinvest.ru/jour/article/view/536 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|